Immune response to lytic peptides conjugated to a betaCG fragment in treated BALB/C mice

Marek Bogacki1, Frederic M Enright, William J Todd

  • 1Institute of Animal Reproduction and Food Research, PAS, Tuwima St. 10, Olsztyn 10-747, Poland. marbo@pan.olsztyn.pl

Reproductive Biology
|August 5, 2008
PubMed

Insights

Hecate-betaCG and Phor14-betaCG(ala) peptides show potential for cancer treatment by selectively destroying cancer cells. These peptides were found to be non-immunogenic and rapidly metabolized, with no antibody formation observed in mice.

Area of Science:

  • Biochemistry
  • Oncology
  • Immunology

Background:

  • Hecate-betaCG and Phor14-betaCG(ala) are short, amphipathic alpha-helical cationic peptides.
  • These peptides demonstrate selective cytotoxicity against breast, prostate, and ovarian cancer cells.

Purpose of the Study:

  • To investigate the immunogenicity of Hecate-betaCG and Phor14-betaCG(ala).
  • To assess the effects of these peptides on reproductive organs in normal wild-type mice.

Main Methods:

  • Enzyme-immunoassay was used to detect specific antibodies.
  • Blood concentrations of the peptides were monitored over time.
  • Histopathological examinations were performed on reproductive organs.

Main Results:

  • No specific antibodies were detected in mice treated with Hecate-betaCG and Phor14-betaCG(ala).
  • Peptide blood concentrations decreased significantly, becoming undetectable within 240 minutes.
  • Degenerative changes were observed in the prostate glands, testes, ovaries, and uteri of treated mice.

Conclusions:

  • Hecate-betaCG and Phor14-betaCG(ala) are non-immunogenic and rapidly metabolized.
  • Despite observed reproductive organ changes, their non-immunogenic nature supports further investigation as potential cancer therapeutics.